BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
BCRX Stock | USD 7.78 0.21 2.77% |
Slightly above 70 percent of all BioCryst Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that a large number of traders are confidant. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
Q2 2023 ORLADEYO net revenue of 81.0 million On-track to achieve 320 million in full year 2023 ORLADEYO revenue and 1 billion in peak ORLADEYO revenue Q2 2023 GAAP EPS of , non-GAAP EPS of , excluding on
Read at globenewswire.com
BioCryst Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
70
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioCryst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioCryst Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentAcquiring |
BioCryst Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioCryst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
AVXL | Anavex Life | 29.55 | ||||
BIVI | Biovie | 8.42 | ||||
ATRA | Atara Biotherapeutics | 7.02 | ||||
IMUX | Immunic | 7.00 | ||||
MCRB | Seres Therapeutics | 4.90 | ||||
INMB | INmune Bio | 3.41 | ||||
SAVA | Cassava Sciences | 2.55 | ||||
PDSB | PDS Biotechnology | 1.21 | ||||
KZR | Kezar Life | 0.94 | ||||
MDGL | Madrigal Pharmaceuticals | 0.79 | ||||
BPMC | Blueprint Medicines | 0.21 | ||||
APLS | Apellis Pharmaceuticals | 0.21 | ||||
TGTX | TG Therapeutics | 0.19 | ||||
VKTX | Viking Therapeutics | 0.17 | ||||
DAWN | Day One | 0.78 | ||||
CGTX | Cognition Therapeutics | 2.54 | ||||
AXSM | Axsome Therapeutics | 4.17 | ||||
XFOR | X4 Pharmaceuticals | 5.39 | ||||
PIRS | Pieris Pharmaceuticals | 9.39 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.